A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood
Relative Bioavailability of Rosuvastatin (Part 1) and Dabigatran (Part 2) Given Alone and Together With BI 1358894 in Healthy Male Subjects (Open, Single-dose, Fixed Sequence, Two-period Crossover Design in Each Trial Part)
Sponsor: Boehringer Ingelheim
A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 9 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Jan 2020 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
-
Dec 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE1
Status: Not Yet Recruiting → Active Not Recruiting
-
Oct 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .